Iterum Therapeutics to Present Data at IDWeek 2025
Iterum Therapeutics (Nasdaq: ITRM) will present clinical data at IDWeek 2025 in Atlanta, GA, taking place October 19–22, 2025. The company will present two posters and host a Learning Lounge on October 21, 2025 at 1:15 pm EST.
Poster details:
- P784 – "Risk factors for treatment failure in patients with uncomplicated urinary tract infection," presenter Steven I. Aronin, MD; Monday, October 20, 12:15 pm–1:30 pm, Poster Hall B4-5.
- P1208 – "In vitro activity of sulopenem and comparator agents against U.S. Enterobacterales clinical isolates, SENTRY antimicrobial surveillance program, 2023," presenter Steven I. Aronin, MD; Tuesday, October 21, 12:15 pm–1:30 pm, Poster Hall B4-5.
The Learning Lounge presentation is titled "An Overview of Urinary Tract Infection in Adult Women: Focus on Oral Sulopenem," with presenters Steven I. Aronin, MD and Michael Dunne, MD. Posters will be posted on the company's "Publications: Posters & Presentations" page under "Our Science" after the conference ends.
Iterum Therapeutics (Nasdaq: ITRM) presenterà dati clinici all'IDWeek 2025 a Atlanta, GA, in programma dal 19 al 22 ottobre 2025. L'azienda presenterà due poster e ospiterà un Learning Lounge il 21 ottobre 2025 alle 13:15 EST.
Dettagli dei poster:
- P784 – "Fattori di rischio per fallimento del trattamento nei pazienti con infezione urinaria non complicata," relatore Steven I. Aronin, MD; lunedì 20 ottobre, 12:15–13:30, Poster Hall B4-5.
- P1208 – "Attività in vitro di sulopenem e agenti di confronto contro isolati clinici di Enterobacterales statunitensi, programma di sorveglianza antimicrobica SENTRY, 2023," relatore Steven I. Aronin, MD; martedì 21 ottobre, 12:15–13:30, Poster Hall B4-5.
La presentazione del Learning Lounge è intitolata "Panoramica dell'infezione delle vie urinarie nelle donne adulte: focus sul sulopenem orali," con relatori Steven I. Aronin, MD e Michael Dunne, MD. I poster saranno pubblicati sulla pagina dell'azienda "Publications: Posters & Presentations" sotto "Our Science" dopo la chiusura della conferenza.
Iterum Therapeutics (Nasdaq: ITRM) presentará datos clínicos en IDWeek 2025 en Atlanta, GA, que se celebrará del 19 al 22 de octubre de 2025. La empresa presentará dos pósters y organizará un Learning Lounge el 21 de octubre de 2025 a las 1:15 p.m. EST.
Detalles de los pósters:
- P784 – "Factores de riesgo de fracaso del tratamiento en pacientes con infección urinaria no complicada," ponente Steven I. Aronin, MD; lunes 20 de octubre, 12:15–13:30, Poster Hall B4-5.
- P1208 – "Actividad in vitro de sulopenem y agentes comparadores frente a aislados clínicos de Enterobacterales de EE. UU., programa de vigilancia antimicrobiana SENTRY, 2023," ponente Steven I. Aronin, MD; martes 21 de octubre, 12:15–13:30, Poster Hall B4-5.
La presentación del Learning Lounge se titula "Una visión general de las infecciones del tracto urinario en mujeres adultas: enfoque en sulopenem oral," con ponentes Steven I. Aronin, MD y Michael Dunne, MD. Los pósters se publicarán en la página de la empresa "Publications: Posters & Presentations" bajo "Our Science" después de que termine la conferencia.
Iterum Therapeutics (나스닥: ITRM)은 2025년 10월 19–22일 조지아주 애틀랜타에서 열리는 IDWeek 2025에서 임상 데이터를 발표할 예정입니다. 회사는 두 개의 포스터를 발표하고 2025년 10월 21일 오후 1:15 EST에 Learning Lounge를 주최합니다.
포스터 상세:
- P784 – "비합병성 요로감염 환자에서 치료 실패의 위험 요인," 발표자: Steven I. Aronin, MD; 10월 20일 월요일, 12:15–13:30, Poster Hall B4-5.
- P1208 – "미국 Enterobacterales 임상 분리주에 대한 sulopenem 및 비교 약물의 시험관 내 활성, SENTRY 항균 감시 프로그램, 2023," 발표자: Steven I. Aronin, MD; 10월 21일 화요일, 12:15–13:30, Poster Hall B4-5.
Learning Lounge 발표 제목은 "성인 여성의 요로감염 개요: 경구 sulopenem에 초점," 발표자: Steven I. Aronin, MD 및 Michael Dunne, MD. 포스터는 학회가 종료된 후 회사의 "Publications: Posters & Presentations" 페이지의 "Our Science" 아래에 게시됩니다.
Iterum Therapeutics (Nasdaq : ITRM) présentera des données cliniques lors de l'IDWeek 2025 à Atlanta, GA, qui se tiendra du 19 au 22 octobre 2025. L'entreprise présentera deux posters et organisera un Learning Lounge le 21 octobre 2025 à 13 h 15 EST.
Détails des posters :
- P784 – "Facteurs de risque d’échec du traitement chez les patients atteints d’infection urinaire non compliquée," présentateur Steven I. Aronin, MD; lundi 20 octobre, 12:15–13:30, Poster Hall B4-5.
- P1208 – "Activité in vitro de sulopenem et d’agents comparateurs contre des isolats cliniques de Enterobacterales américains, programme de surveillance antimicrobienne SENTRY, 2023," présentateur Steven I. Aronin, MD; mardi 21 octobre, 12:15–13:30, Poster Hall B4-5.
La présentation Learning Lounge est intitulée "Aperçu de l'infection urinaire chez les femmes adultes : focus sur le sulopenem oral," avec les présentateurs Steven I. Aronin, MD et Michael Dunne, MD. Les posters seront publiés sur la page de l'entreprise "Publications: Posters & Presentations" sous "Our Science" après la fin de la conférence.
Iterum Therapeutics (Nasdaq: ITRM) wird auf der IDWeek 2025 in Atlanta, GA, Daten aus klinischen Studien vorstellen, die vom 19. bis 22. Oktober 2025 stattfinden. Das Unternehmen wird zwei Poster präsentieren und am 21. Oktober 2025 um 13:15 Uhr EST einen Learning Lounge veranstalten.
Poster-Details:
- P784 – "Risikofaktoren für Behandlungserfolg oder -scheitern bei Patienten mit unkomplizierter HWI," Referent Steven I. Aronin, MD; Montag, 20. Oktober, 12:15–13:30 Uhr, Poster Hall B4-5.
- P1208 – "In vitro-Aktivität von Sulopenem und Vergleichssubstanzen gegenüber US-amerikanischen Enterobacterales-klinischen Isolaten, SENTRY Antimikrobielle Überwachungsprogramm, 2023," Referent Steven I. Aronin, MD; Dienstag, 21. Oktober, 12:15–13:30 Uhr, Poster Hall B4-5.
Die Learning Lounge-Präsentation trägt den Titel "Überblick über HWI bei erwachsenen Frauen: Fokus auf orales Sulopenem," mit den Referenten Steven I. Aronin, MD und Michael Dunne, MD. Die Poster werden auf der Unternehmensseite "Publications: Posters & Presentations" unter "Our Science" veröffentlicht, nachdem die Konferenz beendet ist.
Iterum Therapeutics (بورصة ناسداك: ITRM) ستقدم بيانات سريرية في IDWeek 2025 في أتلانتا، جورجيا، التي ستعقد في الفترة من 19 إلى 22 أكتوبر 2025. ستقدم الشركة لوحين وتستضيف Learning Lounge في 21 أكتوبر 2025 في الساعة 1:15 مساءً بتوقيت شرق الولايات المتحدة.
تفاصيل الملصقات:
- P784 – "عوامل الخطر لفشل العلاج لدى المرضى المصابين بعدوى المسالك البولية غير المعقدة"، مقدم العرض: د. ستيفن آ. أرونين، MD؛ الاثنين 20 أكتوبر، 12:15–13:30، قاعة الملصقات B4-5.
- P1208 – "النشاط في المختبر لسولوبينيم وعوامل مقارِنة ضد عزلات سريرية من Enterobacterales الأمريكية، برنامج المراقبة المضادّة للميكروبات SENTRY، 2023"، مقدم العرض: د. ستيفن آ. أرونين، MD؛ الثلاثاء 21 أكتوبر، 12:15–13:30، قاعة الملصقات B4-5.
عنوان عرض Learning Lounge هو "نظرة عامة على عدوى المسالك البولية لدى النساء البالغات: تركيز على سولوبينيم الفموي"، مع مقدِّمي العرض د. ستيفن آ. أرونين، MD و د. مايكل دان، MD. ستُنشر الملصقات على صفحة الشركة "Publications: Posters & Presentations" ضمن "Our Science" بعد انتهاء المؤتمر.
Iterum Therapeutics (纳斯达克：ITRM) 将在 Atlanta, GA 举行的 IDWeek 2025 上发布临床数据，时间为 2025 年 10 月 19–22 日。公司将发表两个海报并于 2025 年 10 月 21 日举办 Learning Lounge，时间为 EST 1:15 pm。
海报详情：
- P784 – "非并发性泌尿道感染患者治疗失败的风险因素," 主讲人 Steven I. Aronin, MD；10 月 20 日，星期一，12:15–13:30，Poster Hall B4-5。
- P1208 – "对美国 Enterobacterales 临床分离株的 sulopenem 及对照药物的体外活性，SENTRY 抗菌监测计划，2023," 主讲人 Steven I. Aronin, MD；10 月 21 日，星期二，12:15–13:30，Poster Hall B4-5。
Learning Lounge 演讲题为 "成人女性尿路感染概览：关注口服 sulopenem," 主讲人 Steven I. Aronin, MD 及 Michael Dunne, MD。海报将在会议结束后发布在公司页面的 "Publications: Posters & Presentations" 页面下的 "Our Science"。
- None.
- None.
DUBLIN and CHICAGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that two posters will be presented at the Infectious Disease Society of America’s IDWeek 2025 conference taking place in Atlanta, GA from October 19-22, 2025.
The Company will also be conducting a Learning Lounge at IDWeek 2025 on Tuesday, October 21, 2025, 1:15 pm EST. The title of the presentation is ‘An Overview of Urinary Tract Infection in Adult Women: Focus on Oral Sulopenem.’ Presenters: Steven I. Aronin, M.D. and Michael Dunne, M.D.
Data to be presented at IDWeek 2025 include:
Presentation Title: Risk factors for treatment failure in patients with uncomplicated urinary tract infection
Poster #: P784
Presenter: Steven I. Aronin, MD
Time/Location: Monday, October 20, 12:15 p.m. - 1:30 p.m., Poster Hall B4-5
Presentation Title: In vitro activity of sulopenem and comparator agents against U.S. Enterobacterales clinical isolates, SENTRY antimicrobial surveillance program, 2023
Poster #: P1208
Presenter: Steven I. Aronin, MD
Time/Location: Tuesday, October 21, 12:15 p.m. - 1:30 p.m., Poster Hall B4-5
These Posters will be made available on the Company’s website on the “Publications: Posters & Presentations” page under the “Our Science” tab once the conference ends.
About ORLYNVAH™
ORLYNVAH™ is a novel oral penem antibiotic for the treatment of uncomplicated urinary tract infections (uUTIs). ORLYNVAH™ possesses potent activity against species of Enterobacterales including those that encode extended spectrum beta-lactamases (ESBL) or AmpC-type ß-lactamases that confer resistance to third generation cephalosporins.
About Iterum Therapeutics plc
Iterum Therapeutics plc is focused on delivering differentiated anti-infectives aimed at combatting the global crisis of multi-drug-resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum has received U.S. Food and Drug Administration approval for ORLYNVAH™ (oral sulopenem) for the treatment of uUTIs caused by Escherichia coli, Klebsiella pneumoniae or Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options, and ORLYNVAH™ is commercially available in the United States. Iterum has also been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit www.iterumtx.com.
Investor Contact:
Judy Matthews
Chief Financial Officer
872-225-6077
IR@iterumtx.com
FAQ
When will Iterum Therapeutics (ITRM) present at IDWeek 2025?
What time is the Iterum Learning Lounge at IDWeek 2025 for ITRM?
What is Poster P784 presented by Iterum (ITRM) at IDWeek 2025?
What is Poster P1208 from Iterum (ITRM) at IDWeek 2025 about?
Where will Iterum (ITRM) post the IDWeek 2025 posters after the conference?
